Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue
A double-blinded, randomized, controlled trial
Emile R. Mohler, III, MD, FACC*,*,
William R. Hiatt, MD ,
Jeffrey W. Olin, DO, FACC ,
Michael Wade, PhD ,
Roger Jeffs, PhD and
Alan T. Hirsch, MD, FACC||
* University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
University of Colorado Health Sciences Center and Colorado Prevention Center, Denver, Colorado, USA
Mount Sinai School of Medicine, New York, New York, USA
United Therapeutics, Research Triangle Park, North Carolina, USA
|| University of Minnesota Medical School, Minneapolis, Minnesota, USA
View larger version (17K):
[in a new window]
|
Figure 1 Study design for this trial. The current study was prospective, randomized, and placebo-controlled, with identical outcome measures and treadmill protocol as in the previously published BERCI-2 study (16). MWD = maximum walking distance; PFWD = pain-free walking distance; TID = three times a day.
|
|
View larger version (19K):
[in a new window]
|
Figure 2 Graph showing maximum walking distance (MWD) (top panel) and pain-free maximum walking distance (PFWD) (bottom panel) for beraprost (diamonds) and placebo (squares). There was no significant difference in MWD and PFWD between beraprost and placebo.
|
|
View larger version (24K):
[in a new window]
|
Figure 3 Graph showing percentage change from baseline in MWD (top panel) and PFWD (bottom panel) for beraprost (diamonds) and placebo (squares). There was no significant difference in MWD and PFWD between beraprost and placebo. Abbreviations as in Figure 2.
|
|
|
